Synonymous mutations frequently act as driver mutations in human cancers
View abstract on PubMed
Summary
This summary is machine-generated.Synonymous mutations, previously considered "silent," significantly contribute to human cancer by affecting gene splicing. These mutations are selected in oncogenes and tumor suppressors, impacting cancer development.
Area Of Science
- Genetics
- Cancer Biology
- Molecular Biology
Background
- Synonymous mutations alter DNA sequence without changing protein sequence.
- These mutations are often considered neutral or
- silent
- in their functional impact.
Purpose Of The Study
- To investigate the role of synonymous mutations in human cancer.
- To determine if synonymous mutations are under selection in cancer genes.
- To explore the functional consequences of selected synonymous mutations.
Main Methods
- Analysis of synonymous mutations in oncogenes and tumor suppressor genes.
- Cancer-type specific selection analysis.
- Investigation of exonic splicing regulatory motifs.
- Assessment of mutations in 3' untranslated regions (UTRs).
Main Results
- Synonymous mutations are frequently selected in human cancers, with cancer-type specificity.
- Selected synonymous mutations often alter splicing regulatory motifs, impacting oncogene splicing.
- Recurrent synonymous mutations in TP53 inactivate splice sites.
- Estimated 6%-8% of selected single-nucleotide changes in oncogenes are synonymous mutations.
- Dosage-sensitive oncogenes show selected mutations in their 3' UTRs.
Conclusions
- Synonymous mutations are not always silent and play a significant role in cancer development.
- Splicing alterations driven by synonymous mutations are a key mechanism in oncogenesis.
- The impact of synonymous mutations is context-dependent, varying between oncogenes and tumor suppressors.